Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial evaluates whether loncastuximab tesirine and rituximab followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone works to treat patients with high risk diffuse large B-cell lymphoma. Loncastuximab tesirine is a monoclonal antibody called loncastuximab, linked to a drug called tesirine. It is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and delivers tesirine to kill them. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Chemotherapy drugs such as doxorubicin, vincristine, and cyclophosphamide work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving loncastuximab tesirine and rituximab in combination with dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone may be more effective at treating high risk diffuse large B-cell lymphoma patients than standard treatments.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony chłoniak z dużych komórek B o wysokim ryzyku (specyficzne cechy zdiagnozowane przez lekarza).
- •Widoczna choroba na skanach obrazowych (CT lub PET/CT).
- •Pacjenci w wieku 18 lat lub starsi.
- •Ogólny stan zdrowia pozwalający na udział w badaniu (oceniany przez lekarza).
✗ Disqualifies
- •Pacjenci, którzy już zaczęli leczenie.
- •Znaczne problemy z nerkami, wątrobą lub sercem.
- •Niewystarczające wyniki badań krwi (np. zbyt mało białych krwinek, płytek krwi lub hemoglobiny).
- •Kobiety w ciąży lub karmiące piersią, a także mężczyźni i kobiety, którzy nie chcą stosować skutecznej antykoncepcji podczas badania.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 30, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
University of California Davis Comprehensive Cancer Center
Sacramento, United States
UC San Diego Moores Cancer Center
San Diego, United States
Trial contact
Office of Clinical Research
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.